[Pregnancy, contraception and HRT and venous thromboembolism]
- PMID: 17626321
[Pregnancy, contraception and HRT and venous thromboembolism]
Abstract
Endogeneous and exogeneous hormonal factors may favor venous thromboembolism (VTE) in the woman. Pregnancy and post-partum, combined contraception and hormonal replacement therapy (HRT) of menopause are associated with an increased risk of VTE. Even when the relative risk is statistically significant, the absolute risk remains generally low unless additional factors are present. The occurrence of a thrombosis depends on the conditions associated to these risk factors: multiparity, caesarean section, type of contraception or HRT, and also on risk factors associated to the woman such as age, obesity, personal history of VTE, hereditary or acquired thrombophilia. The detection of high-risk women because of personal history of VTE, associated risk factors and/or thrombophilia should improve the clinical management and thrombosis prophylaxis, especially when hormonal treatments are prescribed.
Similar articles
-
Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: a clinical review.Arch Intern Med. 2004 Oct 11;164(18):1965-76. doi: 10.1001/archinte.164.18.1965. Arch Intern Med. 2004. PMID: 15477430 Review.
-
Sex and gender issues and venous thromboembolism.Clin Chest Med. 2004 Jun;25(2):281-97. doi: 10.1016/j.ccm.2004.01.013. Clin Chest Med. 2004. PMID: 15099889 Review.
-
Inherited thrombophilia and gestational venous thromboembolism.Semin Thromb Hemost. 2003 Apr;29(2):131-42. doi: 10.1055/s-2003-38828. Semin Thromb Hemost. 2003. PMID: 12709916 Review.
-
Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy.Thromb Haemost. 2000 Apr;83(4):530-5. Thromb Haemost. 2000. PMID: 10780311
-
Thrombophilia and the risk for venous thromboembolism during pregnancy, delivery, and puerperium.Obstet Gynecol Clin North Am. 2006 Sep;33(3):413-27. doi: 10.1016/j.ogc.2006.05.009. Obstet Gynecol Clin North Am. 2006. PMID: 16962918 Review.
Cited by
-
Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms.Oncotarget. 2015 Jul 10;6(19):17621-36. doi: 10.18632/oncotarget.4184. Oncotarget. 2015. PMID: 26056044 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical